Last reviewed · How we verify
NCT05546281: Santal-DT1
Study of the Characteristics of Orthorexia Nervosa in the Population Living with Type 1 Diabetes
trial testing No intervention in Type 1 Diabetes in 33 participants. Completed in 1 May 2024.
1 April 2024
Quick facts
| Lead sponsor | Laval University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 33 |
| Start date | 1 October 2022 |
| Primary completion | 1 April 2024 |
| Estimated completion | 1 May 2024 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- No intervention
Conditions studied
- Type 1 Diabetes — all drugs for Type 1 Diabetes →
Sponsor
Laval University
Who can join
Adults 18 to 35, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the general population, the excessive and constant desire to control one's diet and body has become increasingly problematic. Indeed, the demand for control over one's diet and body is now an unspoken social prescription that can lead in some cases to eating disorders. In patients with type 1 diabetes (T1D), these concerns are even more central, as they are accentuated by the very nature of the treatment of the disease (dietary modification, insulin compensation according to food intake, etc.). Studies on adolescents with T1D show that the prevalence of eating disorders would be present in at least 1 in 5 patients. Among these disorders, orthorexia is of particular interest. Indeed, orthorexia was defined in 1997 by Steven Bratman as a rigid eating behavior based on the avoidance of foods considered qualitatively unhealthy. More precisely, orthorexia is characterized by a constant preoccupation with one's diet and persistent nutritional (or health) beliefs that take precedence over food pleasure. It has been estimated that the prevalence of orthorexia in patients living with T1D may be as high as 80%. We are currently conducting a study on the mechanisms of orthorexia in the general population of Quebec (the results of phase 1 of this study are being analyzed). We now wish to conduct the same study in a population with T1D, which has a higher prevalence of people with orthorexia nervosa. The main objective of this study is to investigate the characteristics of orthorexia nervosa (obsessions and fixations on healthy eating) in the Quebec population with T1D from the BETTER Registry.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05546281
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other recruiting trials for Type 1 Diabetes
Currently open trials in the same condition.
- NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
- NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
- NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
- NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
- NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting
Other Laval University trials
Trials by the same sponsor.
- NCT07491887 — Identification of Objective Metabolomics-based Biomarkers of Yogurt Consumption · NA · not yet recruiting
- NCT07366827 — Effectiveness of Motorised Lumbar Support for Non-specific Low Back Pain · NA · not yet recruiting
- NCT07317973 — A Study About Patient Decision Aids Designed to Help Parents and Guardians in Canada Make Evidence-informed, Values-cong · NA · not yet recruiting
- NCT07293312 — Optimizing the Use of Virtual Reality in Rehabilitation for Individuals With Persistent Shoulder Pain · NA · not yet recruiting
- NCT07201870 — Digital Preparation for Bariatric Surgery: Feasability Pilot Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05546281 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Laval University
- Last refreshed: 9 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05546281.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing